|
DrugPatentWatch concentrates deep knowledge on more than 6,400 small-molecule drugs and 2,300 generic ingredients from 1,700 branded and generic pharmaceutical companies and 700 suppliers, and more than 4,300 active and expired US patents and 74,000 international patents spanning 93 countries and regional patent offices. |
Tradename: ATACAND
Summary for Tradename: ATACAND
|
| |||||||||||
Clinical Trials for: ATACANDEvaluation of the Pharmacokinetic Interaction Between Candesartan and Felodipine After Ingestion of a Specific Meal Status: Completed Condition: Healthy ARIA (Atacand Renoprotection In NephropAthy Pt.) Status: Completed Condition: Non-diabetic Nephropathy With Hypertension Candesartan Effect in Second Stage Arterial Hypertension Status: Completed Condition: Stage II Hypertension Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age Status: Completed Condition: Hypertension Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide Status: Completed Condition: Essential Hypertension Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo Status: Completed Condition: Hypertension Pivotal Bioequivalence FDC Nifedipine / Candesartan vs. Loose Combination of Single Components, Fed Status: Completed Condition: Hypertension Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVH Status: Completed Condition: Essential Hypertension; Left Ventricular Hypertrophy Open-Label Long-Term Safety and Efficacy Study of Fixed Dose Combination of Nifedipine Gastrointestinal Therapeutic System and Candesartan Cilexetil in Subjects With Moderate to Severe Essential Hypertension Status: Recruiting Condition: Hypertension Single Dose Bioequivalence Study Comparing Nifedipine/Candesartan FDC (Fixed Dose Combination) With Loose Combination of Nifedipine GITS (Gastro-intestinal Therapeutic System) Plus Candesartan and Single Components Under Fasting Conditions Status: Completed Condition: Hypertension Courtesy of ClinicalTrials.org See more clinical trials for this drug | ||||||||||||
Glossary
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Type | RLD | Patent No. | Product | Substance | Delist_Flag | Patent Expiration | Exclusivity Expiration | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astrazeneca | ATACAND | candesartan cilexetil | TABLET; ORAL | 020838 | Jun 4, 1998 | RX | No | 5,196,444*PED | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Astrazeneca | ATACAND | candesartan cilexetil | TABLET; ORAL | 020838 | Jun 4, 1998 | RX | No | 5,534,534*PED | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Astrazeneca | ATACAND | candesartan cilexetil | TABLET; ORAL | 020838 | Jun 4, 1998 | RX | Yes | 5,196,444*PED | <disabled> | <disabled> | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Astrazeneca | ATACAND | candesartan cilexetil | TABLET; ORAL | 020838 | Jun 4, 1998 | RX | Yes | 5,534,534*PED | Y | <disabled> | <disabled> | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| The preview shows a limited data set. Complete access is available with a Subscription | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Paragraph IV activity for: ATACAND
| Drugname | Dosage | Strength | RLD | Submissiondate |
| candesartan cilexetil and hydrochlorothiazide | Tablets | 32 mg/25 mg | Atacand HCT | 3/6/2009 |
| candesartan cilexetil and hydrochlorothiazide | Tablets | 16 mg/12.5 mg and 32 mg/12.5 mg | Atacand HCT | 6/25/2008 |
| candesartan cilexetil | Tablets | 4 mg, 8 mg, 16 mg and 32 mg | Atacand | 12/22/2006 |
« Back to Dashboard
DrugPatentWatch Archives
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Connect with Social Media:
Copyright © 2002-2013 thinkBiotech LLC. ISSN: 2162-2639
`abc